Rocket Pharmaceuticals (RCKT) Other Non-Current Assets (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Other Non-Current Assets data on file, last reported at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 1.54% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 1.54% YoY), and the FY2025 full-year result was $482000.0, down 8.88% from the prior year.
• Other Non-Current Assets rose to $1.3 million in Q1 2026, from $482000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $1.4 million in Q2 2025 to a low of $455000.0 in Q1 2022.
• A 5-year average of $1.0 million and a median of $1.3 million in 2022 frame the typical range for Other Non-Current Assets.
• Peak annual rise in Other Non-Current Assets reached 195.16% in 2022, while the deepest fall reached 68.86% in 2022.
• Tracing RCKT's Other Non-Current Assets over 5 years: stood at $1.3 million in 2022, then slumped by 60.22% to $533000.0 in 2023, then decreased by 0.75% to $529000.0 in 2024, then slipped by 8.88% to $482000.0 in 2025, then jumped by 178.22% to $1.3 million in 2026.
• Business Quant data shows RCKT's Other Non-Current Assets at $1.3 million in Q1 2026, $482000.0 in Q4 2025, and $1.4 million in Q3 2025.